Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
New York, New York–(Newsfile Corp. – January 13, 2025) – WHY: The Rosen Law Firm, a global investment rights law firm, announces the filing of a class action lawsuit on behalf of buyers of BioAge Labs, Inc. stock. (NASDAQ: BIOA) pursuant to and/or attributable to BioAge’s initial public offering on September 26. , 2024 (“IPO”). A class action lawsuit has been filed. If you wish to act as the lead plaintiff, you must remove the Court before March 10, 2025.
NOW: If you purchased BioAge stock you may be entitled to compensation without payment of any out-of-pocket costs or expenses through a contingency fee arrangement.
WHAT YOU NEED TO DO: To join the BioAge class action, go to https://rosenlegal.com/submit-form/?case_id=33167 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about a class action. A class action lawsuit has been filed. If you wish to act as the lead plaintiff, you must remove the Court before March 10, 2025. The lead plaintiff is the party representing the other members of the class to conduct the case.
WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Oftentimes, the companies that issue the notices don’t have the experience, the resources, or any meaningful peer recognition. Be smart when choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder litigation. The Rosen Law Firm achieved the largest defense settlement against a Chinese Company at that time. Rosen Law Firm is ranked No. 1 by ISS Securities Group Action (WA:) Securities ranking services in 2017. The firm has been ranked 4th every year since 2013 and has earned hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Most of the firm’s lawyers are recognized by Lawdragon and Super Lawyers.
FACTS OF THE CASE: According to the indictment, the defendants presented its first product candidate azelaprag in connection with BioAge’s ongoing STRIDES clinical trial with expectations of primary results in 2025. The defendants also mentioned their partnership with Eli Lilly and Company (NYSE:)’s (“Lilly”) Chorus. the clinical development organization will be advising and assisting in all aspects of the design and implementation of the STRIDES trial. The defendants also discussed the possibility of a second Phase 2 clinical trial combining azelaprag and semaglutide to treat obesity in people 18 years of age and older. Therefore, the IPO informed the public that there are no safety concerns and that BioAge is expected to achieve the main results and meet its main objectives regarding its STRIDES clinical trial.
Contrary to these recommendations, BioAge has stopped the ongoing STRIDES Phase 2 study of azelaprag after several studies showed elevated levels of liver enzymes that warn of potential damage. be present in the body. As a result, the defendants discontinued the clinical trial and stopped further registration. Due to the fact that the defendants failed to reveal the ability to transaminitis the liver in any of its early clinical trials Phase 1 and various preclinical tox studies, the defendants’ statements in the BioAge registration statement was false and/or materially misleading at the time of the IPO. When the real facts entered the market, the lawsuit alleges that investors were harmed.
To join the BioAge class action, go to https://rosenlegal.com/submit-form/?case_id=33167 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about a class action.
No Group Guaranteed. Until the group is confirmed, you are not represented by a counselor unless you have reserved one. You can choose a consultant of your choice. You can remain a member of the missing group and do nothing at this point. The investor’s ability to contribute to future recovery does not depend on serving as the primary plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https: / /www.facebook.com/rosenlawfirm/.
Advertising Attorney. Preliminary results do not guarantee a similar outcome.
——————————
To view the source version of this release, please visit https://www.newsfilecorp.com/release/237075
